THIS SITE IS INTENDED FOR U.S. HCP AUDIENCES ONLY
MORE
  • Study
    Design
  • MOA
  • Initiation
    and Dosing

Powerful Efficacy of ZEPOSIA


ZEPOSIA DELIVERS POWERFUL EFFICACY VS AVONEX

Proven Superior vs Avonex in Reducing ARR1a

Chart showing absolute ARR (annualized relapse rate) for Zeposia® and Avonex, proven in 2 clinical trials (1-year and 2-year study)
Absolute ARR for ZEPOSIA
  • SUNBEAM 0.18
  • RADIANCE 0.17

aA relapse was defined as the occurrence of new or worsening neurological symptoms persisting for more than 24 hours attributable to MS and immediately preceded by a relatively stable or improving neurological state of at least 30 days.2,3

ARR=annualized relapse rate.

Most Patients Experienced ZERO Relapses

The Majority of Patients Had No Relapses in Clinical Trials1a

Percent of Patients Who Were Without Relapse

Results of the SUNBEAM
(1 Year) Clinical Trial
78%
of patients treated with ZEPOSIA (n=447) were without relapse vs 66% of patients treated with
Avonex (n=448)
Results of the RADIANCE
(2 Years) Clinical Trial
76%
of patients treated with ZEPOSIA (n=433) were without relapse vs 64% of patients treated with
Avonex (n=441)

aA relapse was defined as the occurrence of new or worsening neurological symptoms persisting for more than 24 hours attributable to MS and immediately preceded by a relatively stable or improving neurological state of at least 30 days.2,3

The Mean Number of Relapses Experienced During the 12 Months Prior to Initiating Therapy Was 1.3 for Both SUNBEAM and RADIANCE1

ZEPOSIA—Proven Superior to Avonex in Reducing Lesions Across All Secondary Measures of MRI Activity

Significant Reductions vs Avonex Across All Secondary Measures of MRI Activity1

GdE Lesions
T2 Lesions

Up to 63% Fewer GdE Lesions vs Avonex1

Chart showing reduction of GdE Lesions in 2 Zeposia® clinical trials with up to 63% fewer GdE Lesions for 1-year and 53% reduction for 2-year study vs Avonex

GdE Lesions at Baseline

The mean number of GdE lesions observed in patients at baseline for both ZEPOSIA and Avonex was 1.8 in SUNBEAM and 1.7 in RADIANCE2,3

In the 1-year SUNBEAM study, brain MRIs were performed at baseline, Month 6, and Month 12.2

In the 2-year RADIANCE study, brain MRIs were performed at baseline, Month 12, and Month 24.3

GdE=gadolinium enhancing.

Up to 48% Fewer New or Enlarging T2 Lesions vs Avonex1

Chart showing a reduction in new or enlarging T2 Lesions in Zeposia® clinical trials with up to 48% fewer new or enlarging T2 lesions in 1-year and 42% in 2-year study vs Avonex

T2 Lesions at Baseline

The mean number of T2 lesions observed in patients at baseline for both ZEPOSIA and Avonex was 54 in SUNBEAM and 48 in RADIANCE2,3

In the 1-year SUNBEAM study, brain MRIs were performed at baseline, Month 6, and Month 12.2

In the 2-year RADIANCE study, brain MRIs were performed at baseline, Month 12, and Month 24.3

9 of 10 Patients Showed No CONFIRMED 3-Month Disability Progression

CDP Results From Clinical Trials1

Disability progression results: 92.4% for Zeposia vs 92.2% for Avonex showed no confirmed 3-month disability progression

92.4% vs 92.2% for Avonex Showed No Confirmed 3-Month Disability Progression

Patients Classified as Having No Disability Progression Did Not Show Sustained Worsening for 3 Consecutive Months1a

7.6% of patients treated with ZEPOSIA (n=67/880) experienced 3‑month CDP, as measured by EDSS, similar to Avonex (7.8%; n=69/889) (P=NS)1,3

Statistical significance was not reached for the pooled confirmed disability progression.3

aCDP was defined as at least a 1-point increase from baseline EDSS sustained for 3 months. CDP was prospectively evaluated in a pooled analysis from SUNBEAM (1 year) and RADIANCE (2 years) studies.1

CDP=confirmed disability progression; EDSS=Expanded Disability Status Scale; NS=nonsignificant.

Quantifying Disability With EDSS4

Picture showing EDSS disability progression scale

Mean EDSS Scores at Baseline

SUNBEAM (1-year study) 2.62

RADIANCE (2-year study) 2.63

ZEPOSIA Was Associated With

A Relative Reduction of Whole Brain Volume Loss of
31% at 1 Year and 26% at 2 Years2,3
Chart showing a relative reduction of whole brain volume loss in Zeposia® clinical trials with 31% in 1-year and 26% in 2-year study vs Avonex

Endpoint was not part of the statistical analysis hierarchy.2,3

In the 1-year SUNBEAM study, brain MRIs were performed at baseline, Month 6, and Month 12.2

In the 2-year RADIANCE study, brain MRIs were performed at baseline, Month 12, and Month 24.3

Brain Atrophy Starts Early and Is an Evolving Measure of Disease Activity5

ZEPOSIA Was Associated With

A Relative Reduction of Cortical Grey Volume Loss of
84% at 1 Year and 60% at 2 Years2,3
Chart showing cortical brain volume loss in Zeposia® clinical trials with 84% relative reduction in 1-year and 60% in 2-year study vs Avonex

Endpoint was not part of the statistical analysis hierarchy.2,3

In the 1-year SUNBEAM study, brain MRIs were performed at baseline, Month 6, and Month 12.2

In the 2-year RADIANCE study, brain MRIs were performed at baseline, Month 12, and Month 24.3

Grey Matter Pathology Affects Both the Cortex and the Thalamus, a Deep Grey Matter Structure6,7

ZEPOSIA Was Associated With

A Relative Reduction of Thalamic Volume Loss of
32% at 1 Year and 27% at 2 Years2,3
Chart showing thalamic volume loss in Zeposia® clinical trials with 32% relative reduction in 1-year and 27% in 2-year study vs Avonex

Endpoint was not part of the statistical analysis hierarchy.2,3

In the 1-year SUNBEAM study, brain MRIs were performed at baseline, Month 6, and Month 12.2

In the 2-year RADIANCE study, brain MRIs were performed at baseline, Month 12, and Month 24.3

Register for More Information

For updates about ZEPOSIA, please provide your contact information below.

*Required
References: 1. ZEPOSIA® (ozanimod) [package insert]. Summit, NJ: Bristol Myers Squibb Company; 2020. 2. Comi G, Kappos L, Selmaj K, et al; for the SUNBEAM Study Investigators. Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (SUNBEAM): a multicentre, randomised, minimum 12-month, phase 3 trial. Lancet Neurol. 2019;18(11):1009-1020. 3. Cohen JA, Comi G, Selmaj K, et al; for the RADIANCE Trial Investigators. Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (RADIANCE): a multicentre, randomised, 24-month, phase 3 trial. Lancet Neurol. 2019;18(11):1021-1033. 4. Kurtzke JF. Rating neurological impairment in multiple sclerosis an Expanded Disability Status Scale. Neurology. 1983;33(11):1444-1452. 5. Ghione E, Bergsland N, Dwyer MG, et al. Brain atrophy is associated with disability progression in patients with MS followed in a clinical routine. AJNR Am J Neuroradiol. 2018;39(12):2237-2242. 6. Damasceno A, Damasceno BP, Cendes F. The clinical impact of cerebellar grey matter pathology in multiple sclerosis. PLoS One. 2014;9(5):e96193. doi:10.1371/journal.pone.0096193 7. Pontillo G, Cocozza S, Lanzillo R, et al. Determinants of deep gray matter atrophy in multiple sclerosis: a multimodal MRI study. AJNR Am J Neuroradiol. 2019;40(1):99-106.

IMPORTANT SAFETY INFORMATION

Indication

ZEPOSIA is indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults.

IMPORTANT SAFETY INFORMATION

Contraindications:

  • Patients who in the last 6 months, experienced myocardial infarction, unstable angina, stroke, transient ischemic attack (TIA), decompensated heart failure requiring hospitalization, or Class III/IV heart failure or have a presence of Mobitz type II second or third-degree atrioventricular (AV) block, sick sinus syndrome, or sino-atrial, unless the patient has a functioning pacemaker
  • Patients with severe untreated sleep apnea
  • Patients taking a monoamine oxidase (MAO) inhibitor

Infections: ZEPOSIA may increase the susceptibility to infections. Life-threatening and rare fatal infections have occurred in patients receiving ZEPOSIA. Obtain a recent (i.e., within 6 months or after discontinuation of prior MS therapy) complete blood count (CBC) including lymphocyte count before initiation of ZEPOSIA. Delay initiation of ZEPOSIA in patients with an active infection until the infection is resolved. Consider interruption of treatment with ZEPOSIA if a patient develops a serious infection. Continue monitoring for infections up to 3 months after discontinuing ZEPOSIA

  • Herpes zoster was reported as an adverse reaction in ZEPOSIA-treated patients. Herpes simplex encephalitis and varicella zoster meningitis have been reported with sphingosine 1-phosphate (S1P) receptor modulators. Patients without a healthcare professional-confirmed history of varicella (chickenpox), or without documentation of a full course of vaccination against varicella zoster virus (VZV), should be tested for antibodies to VZV before initiating ZEPOSIA. A full course of vaccination for antibody-negative patients with varicella vaccine is recommended prior to commencing treatment with ZEPOSIA
  • Cases of fatal cryptococcal meningitis (CM) were reported in patients treated with another S1P receptor modulator. If CM is suspected, ZEPOSIA should be suspended until cryptococcal infection has been excluded. If CM is diagnosed, appropriate treatment should be initiated.
  • Progressive Multifocal Leukoencephalopathy (PML) is an opportunistic viral infection of the brain that typically occurs in patients who are immunocompromised, and that usually leads to death or severe disability. No cases of PML were identified in active-controlled MS clinical trials with ZEPOSIA. PML has been reported in patients treated with S1P receptor modulators and other MS therapies and has been associated with some risk factors. If PML is suspected, withhold ZEPOSIA and perform an appropriate diagnostic evaluation. If confirmed, treatment with ZEPOSIA should be discontinued
  • In clinical studies, patients who received ZEPOSIA were not to receive concomitant treatment with antineoplastic, non-corticosteroid immunosuppressive, or immune-modulating therapies used for treatment of MS. Concomitant use of ZEPOSIA with any of these therapies would be expected to increase the risk of immunosuppression. When switching to ZEPOSIA from immunosuppressive medications, consider the duration of their effects and their mode of action to avoid unintended additive immunosuppressive effects
  • Use of live attenuated vaccines should be avoided during and for 3 months after treatment with ZEPOSIA. If live attenuated vaccine immunizations are required, administer at least 1 month prior to initiation of ZEPOSIA

Bradyarrhythmia and Atrioventricular Conduction Delays: Since initiation of ZEPOSIA may result in a transient decrease in heart rate and atrioventricular conduction delays, dose titration is recommended to help reduce cardiac effects. Initiation of ZEPOSIA without dose escalation may result in greater decreases in heart rate. If treatment with ZEPOSIA is considered, advice from a cardiologist should be sought for those individuals:

  • with significant QT prolongation
  • with arrhythmias requiring treatment with Class 1a or III anti-arrhythmic drugs
  • with ischemic heart disease, heart failure, history of cardiac arrest or myocardial infarction, cerebrovascular disease, and uncontrolled hypertension
  • with a history of Mobitz type II second-degree or higher AV block, sick-sinus syndrome, or sinoatrial heart block

Liver Injury: Elevations of aminotransferases may occur in patients receiving ZEPOSIA. Obtain liver function tests, if not recently available (i.e., within 6 months), before initiation of ZEPOSIA. Patients who develop symptoms suggestive of hepatic dysfunction should have hepatic enzymes checked and ZEPOSIA should be discontinued if significant liver injury is confirmed. Caution should be exercised when using ZEPOSIA in patients with history of significant liver disease

Fetal Risk: There are no adequate and well-controlled studies in pregnant women. Based on animal studies, ZEPOSIA may cause fetal harm. Women of childbearing potential should use effective contraception to avoid pregnancy during treatment and for 3 months after stopping ZEPOSIA

Increased Blood Pressure: Increase in systolic pressure was observed after about 3 months of treatment and persisted throughout treatment. Blood pressure should be monitored during treatment and managed appropriately. Certain foods that may contain very high amounts of tyramine could cause severe hypertension in patients taking ZEPOSIA. Patients should be advised to avoid foods containing a very large amount of tyramine while taking ZEPOSIA

Respiratory Effects: ZEPOSIA may cause a decline in pulmonary function. Spirometric evaluation of respiratory function should be performed during therapy, if clinically indicated

Macular edema: S1P modulators have been associated with an increased risk of macular edema. Patients with a history of uveitis or diabetes mellitus are at increased risk. Patients with a history of these conditions should have an ophthalmic evaluation of the fundus, including the macula, prior to treatment initiation and regular follow-up examinations. An ophthalmic evaluation is recommended in all patients at any time if there is a change in vision. Continued use of ZEPOSIA in patients with macular edema has not been evaluated; potential benefits and risks for the individual patient should be considered if deciding whether ZEPOSIA should be discontinued

Posterior Reversible Encephalopathy Syndrome (PRES): Rare cases of PRES have been reported in patients receiving a S1P receptor modulator. If a ZEPOSIA-treated patient develops unexpected neurological or psychiatric symptoms or any symptom/sign suggestive of an increase in intracranial pressure, a complete physical and neurological examination should be conducted. Symptoms of PRES are usually reversible but may evolve into ischemic stroke or cerebral hemorrhage. Delay in diagnosis and treatment may lead to permanent neurological sequelae. If PRES is suspected, treatment with ZEPOSIA should be discontinued

Unintended Additive Immunosuppressive Effects From Prior Immunosuppressive or Immune-Modulating Drugs: When switching from drugs with prolonged immune effects, the half-life and mode of action of these drugs must be considered to avoid unintended additive immunosuppressive effects while at the same time minimizing risk of disease reactivation. Initiating treatment with ZEPOSIA after treatment with alemtuzumab is not recommended

Severe Increase in Disability After Stopping ZEPOSIA: Severe exacerbation of disease, including disease rebound, has been rarely reported after discontinuation of a S1P receptor modulator. The possibility of severe exacerbation of disease should be considered after stopping ZEPOSIA treatment so patients should be monitored upon discontinuation

Immune System Effects After Stopping ZEPOSIA: After discontinuing ZEPOSIA, the median time for lymphocyte counts to return to the normal range was 30 days with approximately 90% of patients in the normal range within 3 months. Use of immunosuppressants within this period may lead to an additive effect on the immune system, therefore caution should be applied when initiating other drugs 4 weeks after the last dose of ZEPOSIA

Most common Adverse Reactions (≥ 4%): upper respiratory infection, hepatic transaminase elevation, orthostatic hypotension, urinary tract infection, back pain, and hypertension.

For additional safety information, please see the full Prescribing Information and Medication Guide.

ZEPOSIA Delivers Powerful Efficacy vs Avonex

Proven Superior vs Avonex in Reducing ARR1ab

Chart showing absolute ARR (annualized relapse rate) for Zeposia® and Avonex, proven in 2 clinical trials (1-year and 2-year study)
Absolute ARR for ZEPOSIA
  • SUNBEAM 0.18
  • RADIANCE 0.17
ZEPOSIA—Proven Superior to Avonex in Reducing Lesions Across All Secondary Measures of MRI Activity

Significant Reductions vs Avonex Across All Secondary Measures of MRI Activity1

Up to 63% Fewer GdE Lesions vs Avonex1

Chart showing reduction of GdE Lesions in 2 Zeposia® clinical trials with up to 63% fewer GdE Lesions for 1-year and 53% reduction for 2-year study vs Avonex

GdE Lesions at Baseline
The mean number of GdE lesions observed in patients at baseline for both ZEPOSIA and Avonex was 1.8 in SUNBEAM and 1.7 in RADIANCE2,3

In the 1-year SUNBEAM study, brain MRIs were performed at baseline, Month 6, and Month 12.2

In the 2-year RADIANCE study, brain MRIs were performed at baseline, Month 12, and Month 24.3

Up to 48% Fewer New or Enlarging T2 Lesions vs Avonex1

Chart showing a reduction in new or enlarging T2 Lesions in Zeposia® clinical trials with up to 48% fewer new or enlarging T2 lesions in 1-year and 42% in 2-year study vs Avonex

T2 Lesions at Baseline
The mean number of T2 lesions observed in patients at baseline for both ZEPOSIA and Avonex was 54 in SUNBEAM and 48 in RADIANCE2,3

In the 1-year SUNBEAM study, brain MRIs were performed at baseline, Month 6, and Month 12.2

In the 2-year RADIANCE study, brain MRIs were performed at baseline, Month 12, and Month 24.3

9 of 10 Patients Showed No Confirmed 3-Month Disability Progression

CDP Results From Clinical Trials1

Disability progression results: 92.4% for Zeposia vs 92.2% for Avonex showed no confirmed 3-month disability progression

92.4% vs 92.2% for Avonex Showed No Confirmed 3-Month Disability Progression

Patients Classified as Having No Disability Progression Did Not Show Sustained Worsening for 3 Consecutive Months1c

7.6% of patients treated with ZEPOSIA (n=67/880) experienced 3‑month CDP, as measured by EDSS, similar to Avonex (7.8%; n=69/889) (P=NS)1,3

Statistical significance was not reached for the pooled confirmed disability progression.3

aStudy designs: SUNBEAM (1 year; N=1346) and RADIANCE (2 years; N=1313) were multicenter, randomized, double-blind, double-dummy, active treatment-controlled studies of daily oral ozanimod 0.92 mg vs weekly Avonex (interferon beta-1a), 30 μg intramuscular injection. Primary endpoint: The ARR was assessed for ZEPOSIA and Avonex at 1 year and 2 years. Secondary endpoints: The number of GdE lesions and the number of new or enlarging T2 lesions were assessed for ZEPOSIA and Avonex at 1 year and 2 years. In addition, confirmed disability progression was prospectively evaluated for ZEPOSIA and Avonex in a pooled analysis from the 1-year and 2-year studies.
bA relapse was defined as the occurrence of new or worsening neurological symptoms persisting for more than 24 hours attributable to MS and immediately preceded by a relatively stable or improving neurological state of at least 30 days.2,3
cCDP was defined as at least a 1-point increase from baseline EDSS sustained for 3 months. CDP was prospectively evaluated in a pooled analysis from SUNBEAM (1 year) and RADIANCE (2 years) studies.1

ARR=annualized relapse rate; CDP=confirmed disability progression; EDSS=Expanded Disability Status Scale; GdE=gadolinium enhancing; NS=nonsignificant; S1P=sphingosine-1-phosphate.

Avonex® is a registered trademark of Biogen.

References: 1. ZEPOSIA® (ozanimod) [package insert]. Summit, NJ: Bristol Myers Squibb Company; 2020. 2. Comi G, Kappos L, Selmaj K, et al. Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (SUNBEAM): a multicentre, randomised, minimum 12-month, phase 3 trial. Lancet Neurol. 2019;18(11):1009-1020. 3. Cohen J, Comi G, Selmaj K, et al. Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (RADIANCE): a multicentre, randomised, 24-month, phase 3 trial. Lancet Neurol. 2019:18(11):1021-1033.

Are You a Healthcare Professional?

This information is intended for U.S. Healthcare Professionals.